Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chubb
Argus Health
QuintilesIMS
Medtronic
Express Scripts
US Army
Dow
UBS

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,609,709

« Back to Dashboard

Which drugs does patent 8,609,709 protect, and when does it expire?

Patent 8,609,709 protects VIBERZI and is included in one NDA.

This patent has fifty-nine patent family members in thirty-two countries.
Summary for Patent: 8,609,709
Title:Compounds as opioid receptor modulators
Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Inventor(s): Breslin; Henry J. (Lansdale, PA), Cai; Chaozhong (North Wales, PA), He; Wei (Audubon, PA), Kavash; Robert W. (Glenside, PA)
Assignee: Janssen Pharmaceutica, N. V. (Beerse, BE)
Application Number:13/690,041
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,609,709

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,609,709

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,344,011 Compounds as opioid receptor modulators ➤ Sign Up
7,741,356 Compounds as opioid receptor modulators ➤ Sign Up
9,700,542 Compounds as opioid receptor modulators ➤ Sign Up
9,205,076 Compounds as opioid receptor modulators ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Dow
Chubb
Covington
Queensland Health
Moodys
Express Scripts
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.